Christoph Faul

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 845 citations · Full text

Medicine, Hematology, Oncology +13

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

Medicine, Hematology, Oncology +15

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski, Ariel Perez Perez, Pierre Sesques et al. · Blood · 2021 · 441 citations · Full text

Life Sciences, Hematology, Immunology +16

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

Ann‐Christin Pecher, Luca Hensen, Reinhild Klein et al. · JAMA · 2023 · 234 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger et al. · Blood · 2015 · 161 citations · Full text

Medicine, Immunology, Oncology +16